Last reviewed · How we verify
Phase 4 Safety and Immunogenicity Study of Aleph Inactivated Split Influenza Vaccine
The objective of this study was to evaluate the safety and immunogenicity of one inactivated split influenza vaccine, a primarily Chinese-marketed trivalent vaccine.
Details
| Lead sponsor | Beijing Center for Disease Control and Prevention |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 3308 |
| Start date | 2011-08 |
| Completion | 2012-12 |
Conditions
- Healthy
Interventions
- recombinant hepatitis b vaccine
- Aleph influenza vaccine
Primary outcomes
- Incidence rate of adverse events of the inactivated split influenza vaccine — two years
Countries
China